Related Experiment Video
Updated: May 7, 2026

Gonadectomy and Blood Sampling Procedures in the Small Size Teleost Model Japanese Medaka Oryzias latipes
Published on: December 11, 2020
Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans
Shourya Tadisina1, Elizabeth Cristiano2, Thomas Wiegmann3
1Division of Endocrinology, Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
Background:
Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off-label treatment.
Objectives:
The present study was conducted to objectively compare clinical outcomes, including adverse effects in patients receiving clomiphene citrate and testosterone replacement therapy.
Materials And Methods:
This is a retrospective study of data collected through the Veterans Administration Informatics and Computing Infrastructure. We identified 364,976 patients with hypogonadisma or infertility. After one-to-one propensity matching, we identified 2518 individuals in both clomiphene citrate and testosterone replacement therapy treatment groups. Outcomes included new diagnoses of fractures, osteoporosis, polycythemia, thrombosis, hypertension, pulmonary embolism, coronary artery disease, and cerebrovascular accidents, which were evaluated relative to the two treatments. Survival was plotted for both treatments and analyzed by Kaplan‒Meier statistics.
Results:
The incidence of various complications was significantly lower after clomiphene citrate relative to testosterone replacement therapy treatment, including new-onset hypertension (6.04% vs. 10.48%), cerebrovascular accident (0.52% vs. 1.43%), coronary artery disease (1.51% vs. 2.26%), polycythemia (1.07% vs. 2.22%), and osteoporosis (1.15% vs. 2.07%). All-cause mortality was also significantly lower in the clomiphene citrate group (1.83%) relative to testosterone replacement therapy group (10.13%). CC increased testosterone levels relative to baseline in a physiological manner.
Conclusion:
TRT was associated with increased mortality relative to CC. Rates of stroke, coronary artery disease, hypertension, osteoporosis, and polycythemia were also greater in patients receiving TRT. Our results also indicate that CC increased testosterone levels relative to baseline in a physiological manner.
Related Concept Videos
Clinical Trials: Overview
Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
Testosterone: Functions and Regulation
Infertility in Males
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of endometrial...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

